{"entity": "journal", "iuid": "2f51a1c6b043457ea65d638579689b49", "timestamp": "2026-09-25T23:01:00.618Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/journal/Vaccine.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/journal/Vaccine"}}, "title": "Vaccine", "issn": "1873-2518", "issn-l": null, "publications_count": 3, "publications": [{"entity": "publication", "iuid": "8e75083f5b6d40638f7370c34d88b53c", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/8e75083f5b6d40638f7370c34d88b53c.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/8e75083f5b6d40638f7370c34d88b53c"}}, "title": "Comparing methods collecting mucosal secretions and detecting SARS-CoV-2 spike IgA in three laboratories across three countries.", "authors": [{"family": "Bladh", "given": "Oscar", "initials": "O"}, {"family": "Aguilera", "given": "Katherina", "initials": "K"}, {"family": "Sheikh-Mohamed", "given": "Salma", "initials": "S"}, {"family": "Nardulli", "given": "Jessica", "initials": "J"}, {"family": "Bhavsar", "given": "Disha", "initials": "D"}, {"family": "Fitzgerald", "given": "Dylan", "initials": "D"}, {"family": "Singh", "given": "Gagandeep", "initials": "G"}, {"family": "Ward", "given": "Lesley A", "initials": "LA"}, {"family": "Kleiner", "given": "Giulio", "initials": "G"}, {"family": "Chao", "given": "Gary Y C", "initials": "GYC"}, {"family": "Norin", "given": "Nina Greilert", "initials": "NG"}, {"family": "Pongr\u00e1cz", "given": "Tam\u00e1s", "initials": "T"}, {"family": "Gleason", "given": "Charles", "initials": "C"}, {"family": "Berkell", "given": "Matilda", "initials": "M"}, {"family": "\u00c5berg", "given": "Mikael", "initials": "M"}, {"family": "Krammer", "given": "Florian", "initials": "F"}, {"family": "Gommerman", "given": "Jennifer L", "initials": "JL"}, {"family": "Th\u00e5lin", "given": "Charlotte", "initials": "C"}, {"family": "Simon", "given": "Viviana", "initials": "V"}], "type": "comparative study", "published": "2025-10-24", "journal": {"title": "Vaccine", "issn": "1873-2518", "volume": "65", "pages": "127792", "issn-l": null}, "abstract": "Mucosal IgA is key in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Several mucosal vaccines are in development, and consistent methodologies assessing mucosal IgA are crucial for evaluation across clinical trials.\n\nWe compared SARS-CoV-2 ancestral spike-specific IgA and secretory IgA (SIgA) in nasal secretions and saliva from 20 adults enrolled at Danderyd Hospital, Stockholm, Sweden, and 23 adults enrolled at the Icahn School of Medicine at Mount Sinai, New York, USA. Nasal secretions were collected by Nasosorption\u00ae and nasal swabs, and saliva by passive drooling, Salivette\u00ae, and saliva swabs. Antibody levels were measured in all samples using an electrochemiluminescence assay (ECL) and two enzyme-linked immunosorbent assays (ELISAs).\n\nSpike-specific IgA and SIgA levels measured by ECL correlated well with those measured by ELISA across nasal and saliva samples (range 0.42-0.94, p < 0.01), except for saliva collected by saliva swabs yielding lower IgA concentrations and weaker correlations (range - 0.21-0.27). Spike-specific IgA levels also correlated well across collection methods (range 0.7-0.9, p < 0.0001), with a weaker correlation between saliva collected by passive drooling and saliva swab (r = 0.55, p < 0.001). Although antibody levels correlated well between nasal secretions and saliva collected by passive drooling or Salivette\u00ae (range 0.64-0.86, p < 0.01), the overall levels were > 3-fold higher in nasal secretions compared to saliva (p < 0.01).\n\nThis multi-center study demonstrates an overall good comparability between spike-specific IgA and SIgA across assays and collection methods, except for saliva swabs. Our findings suggest that nasal secretions may be preferable due to higher spike-specific IgA levels compared to in saliva.", "doi": "10.1016/j.vaccine.2025.127792", "pmid": "41046839", "labels": [], "xrefs": [{"db": "pii", "key": "S0264-410X(25)01089-8"}], "notes": [], "created": "2026-09-23T12:33:33.445Z", "modified": "2026-09-23T12:33:33.469Z"}, {"entity": "publication", "iuid": "31f943323d324fd4bf94502d9cd663f3", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/31f943323d324fd4bf94502d9cd663f3.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/31f943323d324fd4bf94502d9cd663f3"}}, "title": "Passive immunization of mice with IgY anti-H5N1 protects against experimental influenza virus infection and allows development of protective immunity.", "authors": [{"family": "Eriksson", "given": "Malin", "initials": "M"}, {"family": "Nyl\u00e9n", "given": "Susanne", "initials": "S"}, {"family": "Gr\u00f6nvik", "given": "Kjell-Olov", "initials": "KO"}], "type": "journal article", "published": "2024-11-14", "journal": {"title": "Vaccine", "issn": "1873-2518", "volume": "42", "issue": "25", "pages": "126133", "issn-l": null}, "abstract": "Influenza virus contributes substantially to the global human and animal disease burden. To protect individuals against disease, strategies are needed to minimize the time an individual is at risk of developing disease symptoms. Passive immunization using avian IgY antibodies can protect individuals against a variety of pathogens, including influenza virus. Yet the effect of IgY administration on generation of protective immunity is largely unknown. To address the effect of passive immunization on the host immune response development, adult or aged, male and female C57BL/6NCrl mice received chicken IgY anti-H5N1, normal IgY or PBS intranasally four hours before, and 20 hours after intranasal infection with H1N1 influenza A virus (PR8). The mice receiving cross-reactive IgY anti-H5N1 were protected from disease and developed influenza virus-specific memory T cells similar to control-treated mice. When re-challenged with PR8 35 days post primary infection IgY anti-H5N1-treated mice were fully protected. Moreover, when challenged with heterologous H3N2 influenza A virus (X-31) or with PR8 three months post infection the mice were protected against severe disease and death, albeit a slight transient weight loss was noted. The results show that passive immunization with IgY anti-H5N1 is safe and protects mice against disease induced by influenza virus without inhibiting development of protective immunity after virus exposure. This indicate that passive immunization can be used as prophylactic therapy in combination with immunization to prevent disease.", "doi": "10.1016/j.vaccine.2024.07.034", "pmid": "39019655", "labels": [], "xrefs": [{"db": "pii", "key": "S0264-410X(24)00796-5"}], "notes": [], "created": "2026-09-23T12:24:58.703Z", "modified": "2026-09-23T12:24:58.716Z"}, {"entity": "publication", "iuid": "5671e0725a884dd3bbf854e8a38ff7f4", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/5671e0725a884dd3bbf854e8a38ff7f4.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/5671e0725a884dd3bbf854e8a38ff7f4"}}, "title": "The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA).", "authors": [{"family": "Frodlund", "given": "Martina", "initials": "M"}, {"family": "Nived", "given": "Per", "initials": "P"}, {"family": "Chatzidionysiou", "given": "Aikaterini", "initials": "A"}, {"family": "S\u00f6dergren", "given": "Anna", "initials": "A"}, {"family": "Klingberg", "given": "Eva", "initials": "E"}, {"family": "Bengtsson", "given": "Anders", "initials": "A"}, {"family": "Hansson", "given": "Monika", "initials": "M"}, {"family": "Olsson", "given": "Sophie", "initials": "S"}, {"family": "Pin", "given": "Elisa", "initials": "E"}, {"family": "Klareskog", "given": "Lars", "initials": "L"}, {"family": "Kapetanovic", "given": "Meliha C", "initials": "MC"}], "type": "journal article", "published": "2023-05-11", "journal": {"title": "Vaccine", "issn": "1873-2518", "volume": "41", "issue": "20", "pages": "3247-3257", "issn-l": null}, "abstract": "To elucidate antibody responses after the second and third dose of COVID-19 vaccine in patients with inflammatory rheumatic diseases (IRD) treated with biologic/targeted disease modifying anti-rheumatic drugs (b/ts DMARDs).\n\nAntibody levels to antigens representing spike full length protein and spike S1 were measured before vaccination, 2-12 weeks after the second dose, before and after the third dose using multiplex bead-based serology assay. Positive antibody response was defined as antibody levels over cut off (seropositivity) in seronegative individuals or \u2265 4-fold increase in antibodies in individuals seropositive for both spike proteins.\n\nPatients (n = 414) receiving b/ts DMARDs (283 had arthritis, 75 systemic vasculitis and 56 other autoimmune diseases) and controls (n = 61) from five Swedish regions participated. Treatments groups were: rituximab (n = 145); abatacept (n = 22); Interleukin 6 receptor inhibitors [IL6i (n = 79)]; JAnus Kinase Inhibitors [JAKi (n = 58)], Tumour Necrosis Factor inhibitor [TNFi (n = 68)] and Interleukin12/23/17 inhibitors [IL12/23/17i (n = 42)]. Percentage of patients with positive antibody response after two doses was significantly lower in rituximab (33,8%) and abatacept (40,9%) (p < 0,001) but not in IL12/23/17i, TNFi or JAKi groups compared to controls (80,3%). Higher age, rituximab treatment and shorter time between last rituximab course and vaccination predicted impaired antibody response. Antibody levels collected 21-40 weeks after second dose decreased significantly (IL6i: p = 0,02; other groups: p < 0,001) compared to levels at 2-12 week but most participants remained seropositive. Proportion of patients with positive antibody response increased after third dose but was still significantly lower in rituximab (p < 0,001).\n\nOlder individuals and patients on maintenance rituximab have an impaired response after two doses of COVID-19 vaccine which improves if the time between last rituximab course and vaccination extends and also after an additional vaccine dose. Rituximab patients should be prioritized for booster vaccine doses. TNFi, JAKi and IL12/23/17i does not diminished humoral response to primary and an additional vaccination.", "doi": "10.1016/j.vaccine.2023.03.065", "pmid": "37076360", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC10070777"}, {"db": "pii", "key": "S0264-410X(23)00372-9"}], "notes": [], "created": "2026-09-23T11:19:46.557Z", "modified": "2026-09-23T11:19:46.600Z"}], "created": "2026-09-23T11:19:46.568Z", "modified": "2026-09-23T11:19:46.568Z"}